Bupivacaine Hydrochloride In Dextrose
Injection · trading as Bupivacaine Spinal
Current
FDA shortage record
- Substance
- Bupivacaine Hydrochloride In Dextrose
- Brand name
- Bupivacaine Spinal
- Manufacturer
- Hospira, Inc.
- Dosage form
- Injection
- Presentation
- Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)
- Route(s)
- SUBARACHNOID
- Therapeutic category
- Anesthesia
- Package NDC
0409-3613-01- Initially posted
- 02/20/2018
- Current FDA status
- Current
Reason and context
Reason reported: Other
Next Delivery and Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 844-646-4398.
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- FDA Structured Product Label (SPL set ID
7a8d2539-4422-4312-0298-207ef1a2948e). - FDA UNII identifier:
7TQO7W3VT8. - See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.